“Orbis Research Presents’s, ‘Type 1 Diabetes (Juvenile Diabetes) – Pipeline Review, H1 2016’, provides an overview of the Type 1 Diabetes (Juvenile Diabetes) pipeline landscape”.
The report provides comprehensive information on the therapeutics under development for Type 1 Diabetes (Juvenile Diabetes), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Type 1 Diabetes (Juvenile Diabetes) and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Request a sample of this report @ http://www.orbisresearch.com/contacts/request-sample/145351
– The report provides a snapshot of the global therapeutic landscape of Type 1 Diabetes (Juvenile Diabetes)
– The report reviews pipeline therapeutics for Type 1 Diabetes (Juvenile Diabetes) by companies and universities/research institutes based on information derived from company and industry-specific sources
– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
– The report reviews key players involved Type 1 Diabetes (Juvenile Diabetes) therapeutics and enlists all their major and minor projects
– The report assesses Type 1 Diabetes (Juvenile Diabetes) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
– The report summarizes all the dormant and discontinued pipeline projects
– The report reviews latest news related to pipeline therapeutics for Type 1 Diabetes (Juvenile Diabetes)
Purchase a copy of Type 1 Diabetes (Juvenile Diabetes) – Pipeline Review, H1 2016 visit @ http://www.orbisresearch.com/contact/purchase/145351
Reasons to buy
– Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
– Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
– Identify and understand important and diverse types of therapeutics under development for Type 1 Diabetes (Juvenile Diabetes)
– Identify potential new clients or partners in the target demographic
– Develop strategic initiatives by understanding the focus areas of leading companies
– Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
– Devise corrective measures for pipeline projects by understanding Type 1 Diabetes (Juvenile Diabetes) pipeline depth and focus of Indication therapeutics
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
– Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
AbGenomics International, Inc., Adocia, AiCuris GmbH & Co. KG, Alteogen Inc., Amarantus Bioscience Holdings, Inc., Ambrx, Inc., AntriaBio, Inc., Aphios Corporation, APT Therapeutics, Inc., Araim Pharmaceuticals, Inc., Argos Therapeutics, Inc., Artery Therapeutics, Inc., Astellas Pharma Inc., AstraZeneca Plc, Athersys, Inc., Axxam SpA, Beta-Cell NV, Biocon Limited, Biodel Inc., Biogenomics Limited, BioLineRx, Ltd., BioLingus AG, BioTherapeutics Inc., Boehringer Ingelheim GmbH, Caladrius Biosciences, Inc., Carlina Technologies SAS, Cellectis S.A., Compugen Ltd., Daewoong Pharmaceutical Co., Ltd., Dance Biopharm Inc., Diabetology (Products) Ltd, DiaMedica Inc., Diamyd Medical AB, Diasome Pharmaceuticals, Inc., Dompe Farmaceutici S.p.A., Effimune S.A., Eli Lilly and Company, enGene, Inc, Ensol Biosciences Inc., EpiVax, Inc., Evotec AG, F. Hoffmann-La Roche Ltd., Fate Therapeutics, Inc., Generex Biotechnology Corporation, GeNeuro SA, Geropharm, Gilead Sciences, Inc., GlaxoSmithKline Plc, Grifols, S.A., Heptares Therapeutics Limited, Iltoo Pharma, Innopharmax Inc., IntelliCell BioSciences Inc., Intrexon Corporation, Islet Sciences, Inc., Johnson & Johnson, Kadimastem Ltd., Kamada Ltd., Kasiak Research Private Limited, Kineta, Inc., Kissei Pharmaceutical Co., Ltd., Lexicon Pharmaceuticals, Inc., Ligand Pharmaceuticals, Inc., Lonestar Heart, Inc., MacroGenics, Inc., Medestea Research & Production S.p.A., MedImmune, LLC, Merck & Co., Inc., Meridigen Biotech Co., Ltd., MidaSol Therapeutics LP, Mitsubishi Tanabe Pharma Corporation, NOD Pharmaceuticals, Inc., Novo Nordisk A/S, Noxxon Pharma AG, Oramed Pharmaceuticals, Inc., Orgenesis, Inc., Paras Biopharmaceuticals Finland Oy, Parvus Therapeutics, Inc., Pathfinder Cell Therapy, Inc., Pfizer Inc., PharmaCyte Biotech, Inc., PharmaIN Corporation, Progen Pharmaceuticals Limited, Prometheon Pharma, LLC, Purzer Pharmaceutical Co., Ltd., RedHill Biopharma Ltd., REGiMMUNE Corporation, Sanofi, SEKRIS Biomedical, Inc., Selecta Biosciences, Inc., Sevion Therapeutics, Inc., Strongbridge Biopharma plc, Therapix Biosciences Ltd, Thermalin Diabetes, LLC, Toleranzia AB, Transgene Biotek Limited, UCB S.A., Uni-Bio Science Group Ltd., United Therapeutics Corporation, ViaCyte, Inc., Visionary Pharmaceuticals, Inc., XL-protein GmbH, XOMA Corporation, Zensun (Shanghai) Sci & Tech Co., Ltd.